S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row

20 Stocks Wall Street Analysts Love the Most

Every trading day, between 500 and 800 new recommendations and research reports are issued by sell-side equities research analysts. There are between 300 and 500 brokerages and research houses that issue ratings, price targets and recommendations and more than 5,000 securities around the world that regularly receive coverage from research analysts.

MarketBeat has tracked more than 170,000 distinct analyst recommendations in the last 12 months alone. Given the volume of ratings changes that occur each day, it can be difficult to sift through the noise.

Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when more than a dozen different analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same stock.

This slide show lists the 20 companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

#1 - Sanofi (NASDAQ:SNY)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$60.00 (11.1% Upside)

About Sanofi

Sanofi logoSanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/5/2023Berenberg BankUpgradeHold ➝ Buy
7/14/2023HSBCInitiated CoverageBuy
4/28/2023Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
3/27/2023ArgusBoost Price TargetBuy$55.00 ➝ $60.00
3/27/2023BarclaysUpgradeEqual Weight ➝ Overweight
12/16/2022The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy
12/13/2022Morgan StanleyReiterated RatingOverweight
10/14/2022BarclaysLower Price TargetEqual Weight ➝ Equal Weight€105.00 ➝ €85.00
9/8/2022Morgan StanleyLower Price Target€112.00 ➝ €93.00
9/7/2022Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold€90.00 ➝ €85.00



#2 - Curtiss-Wright (NYSE:CW)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$208.40 (5.4% Upside)

About Curtiss-Wright

Curtiss-Wright logoCurtiss-Wright Corporation, together with its subsidiaries, provides engineered products, solutions, and services to the aerospace, defense, general industrial, and power generation markets worldwide. It operates through three segments: Aerospace & Industrial, Defense Electronics, and Naval & Power. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/7/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$188.00 ➝ $229.00
8/4/2023Robert W. BairdBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $228.00
7/21/2023Truist FinancialBoost Price TargetBuy$190.00 ➝ $211.00
7/19/2023Stifel NicolausBoost Price TargetBuy$200.00 ➝ $204.00
5/19/2023William BlairInitiated CoverageOutperform
4/17/2023Stifel NicolausBoost Price TargetBuy$196.00 ➝ $200.00
2/23/2023Truist FinancialBoost Price TargetBuy$183.00 ➝ $190.00
1/9/2023Truist FinancialBoost Price Target$175.00 ➝ $183.00
12/12/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$187.00 ➝ $188.00
11/7/2022Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $187.00



#3 - West Fraser Timber (NYSE:WFG)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$113.13 (59.2% Upside)

About West Fraser Timber

West Fraser Timber logoWest Fraser Timber Co Ltd., a diversified wood products company, engages in manufacturing, selling, marketing, and distributing lumber, engineered wood products, pulp, newsprint, wood chips, and other residuals and renewable energy. It offers spruce-pine-fir and southern yellow pine lumber, treated wood products, medium density fiberboard panels and plywood, oriented strand board, and laminated veneer lumber wood products, as well as particleboards. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/23/2023CSFBBoost Price TargetOutperform$106.50 ➝ $108.50
8/23/2023Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$106.50 ➝ $109.00
7/27/2023Raymond JamesBoost Price TargetStrong-Buy$120.00 ➝ $125.00
7/25/2023CSFBBoost Price TargetOutperform$92.50 ➝ $106.50
7/24/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$105.00 ➝ $120.00
7/18/2023TD SecuritiesBoost Price TargetBuy$100.00 ➝ $110.00
2/16/2023TD SecuritiesBoost Price TargetBuy$100.00 ➝ $110.00
2/13/2023Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $97.00
1/24/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform$100.00 ➝ $95.00
11/22/2022Credit Suisse GroupInitiated CoverageNeutral$100.00



#4 - Donaldson (NYSE:DCI)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$68.67 (14.6% Upside)

About Donaldson

Donaldson logoDonaldson Company, Inc manufactures and sells filtration systems and replacement parts worldwide. The company operates through two segments, Engine Products and Industrial Products. Its Engine Products segment provides replacement filters for air and liquid filtration applications; air filtration systems; liquid filtration systems for fuel, lube, and hydraulic applications; exhaust and emissions systems and sensors; indicators; and monitoring systems. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/30/2023Robert W. BairdBoost Price TargetOutperform ➝ Outperform$67.00 ➝ $69.00
6/27/2023CitigroupInitiated CoverageNeutral$66.00
4/20/2023Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $71.00
3/3/2023Robert W. BairdBoost Price Target$66.00 ➝ $69.00
3/2/2023Morgan StanleyBoost Price TargetOverweight$66.00 ➝ $70.00
12/1/2022Morgan StanleyBoost Price TargetOverweight$63.00 ➝ $66.00
12/1/2022Robert W. BairdBoost Price TargetOutperform$59.00 ➝ $66.00
9/1/2022Robert W. BairdLower Price TargetOutperform$61.00 ➝ $59.00
7/18/2022Morgan StanleyLower Price TargetOverweight$68.00 ➝ $63.00
7/18/2022Stifel NicolausLower Price Target$53.00 ➝ $51.00



#5 - Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$36.25 (60.3% Downside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/11/2023DNB MarketsDowngradeBuy ➝ Hold
7/14/2023HSBCInitiated CoverageBuy
4/13/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform
12/12/2022CowenBoost Price Target$32.50 ➝ $36.25
12/12/2022CowenBoost Price Target$32.50 ➝ $36.25
11/4/2022Credit Suisse GroupBoost Price Target205.00 ➝ 215.00
9/29/2022Oddo BhfUpgradeNeutral ➝ Outperform
7/15/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
6/28/2022UBS GroupDowngradeNeutral ➝ Sell
6/7/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight



#6 - Everest Group (NYSE:EG)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$434.00 (10.8% Upside)

About Everest Group

Everest Group logoEverest Group, Ltd., through its subsidiaries, provides reinsurance and insurance products in the United States, Bermuda, and internationally. The company operates through Reinsurance Operations and Insurance Operations segments. The Reinsurance Operations segment writes property and casualty reinsurance; and specialty lines of business through reinsurance brokers, as well as directly with ceding companies in the United States, Bermuda, Ireland, Canada, Singapore, Switzerland, and the United Kingdom. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/8/2023The Goldman Sachs GroupInitiated CoverageBuy$449.00
8/9/2023CitigroupBoost Price TargetBuy ➝ Buy$406.00 ➝ $408.00
8/1/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$429.00
7/7/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$420.00 ➝ $450.00



#7 - Textron (NYSE:TXT)

Consensus Rating
Moderate Buy
Rating Score
2.6
Ratings Breakdown
4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$86.00 (10.6% Upside)

About Textron

Textron logoTextron Inc operates in the aircraft, defense, industrial, and finance businesses worldwide. It operates through six segments: Textron Aviation, Bell, Textron Systems, Industrial, Textron eAviation, and Finance. The Textron Aviation segment manufactures, sells, and services business jets, turboprop and piston engine aircraft, and military trainer and defense aircraft; and offers maintenance, inspection, and repair services, as well as sells commercial parts. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/15/2023Bank of AmericaBoost Price TargetNeutral ➝ Neutral$76.00 ➝ $85.00
7/28/2023CitigroupBoost Price TargetBuy$90.00 ➝ $95.00
7/28/2023SusquehannaBoost Price TargetPositive$83.00 ➝ $89.00
7/6/2023CitigroupInitiated CoverageBuy$90.00
5/24/2023Vertical ResearchDowngradeBuy ➝ Hold$70.00
4/6/2023Wolfe ResearchInitiated CoveragePeer Perform
12/15/2022The Goldman Sachs GroupBoost Price TargetBuy$84.00 ➝ $93.00
10/28/2022Morgan StanleyLower Price TargetOverweight$90.00 ➝ $84.00
9/13/2022Sanford C. BernsteinInitiated CoverageMarket Perform
8/9/2022CfraBoost Price Target$73.00



#8 - United Therapeutics (NASDAQ:UTHR)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
8 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$296.44 (33.1% Upside)

About United Therapeutics

United Therapeutics logoUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/3/2023Morgan StanleyBoost Price TargetOverweight ➝ Overweight$316.00 ➝ $318.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00
8/3/2023WedbushBoost Price TargetOutperform ➝ Outperform$305.00 ➝ $307.00
8/3/2023LADENBURG THALM/SH SHBoost Price TargetBuy ➝ Buy$256.00 ➝ $268.00
5/4/2023LADENBURG THALM/SH SHLower Price Target$285.00 ➝ $256.00
4/21/2023ArgusLower Price TargetBuy$300.00 ➝ $280.00
4/10/2023UBS GroupLower Price TargetBuy$330.00 ➝ $310.00
4/10/2023Morgan StanleyLower Price TargetOverweight$320.00 ➝ $316.00
2/23/2023JPMorgan Chase & Co.Boost Price TargetOverweight$265.00 ➝ $280.00
2/23/2023Morgan StanleyLower Price TargetOverweight$330.00 ➝ $320.00



#9 - Tenaris (NYSE:TS)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$43.80 (41.3% Upside)

About Tenaris

Tenaris logoTenaris SA, together with its subsidiaries, produces and sells seamless and welded steel tubular products and related services for the oil and gas industry, and other industrial applications. The company offers steel casings, tubing products, mechanical and structural pipes, line pipes, cold-drawn pipes, and premium joints and couplings; and coiled tubing products for oil and gas drilling and workovers, and subsea pipelines. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/28/2023Jefferies Financial GroupInitiated CoverageBuy$41.80
5/1/2023Piper SandlerLower Price Target$49.00 ➝ $44.00
4/18/2023Morgan StanleyLower Price Target$44.00 ➝ $40.00
2/21/2023Morgan StanleyBoost Price TargetOverweight$42.00 ➝ $44.00
2/17/2023CowenBoost Price Target$45.00 ➝ $49.00
1/4/2023Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $42.00
11/28/2022Grupo SantanderDowngradeOutperform ➝ Neutral
11/18/2022Piper SandlerBoost Price TargetOverweight$33.00 ➝ $45.00
11/15/2022JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $50.00
10/13/2022Stifel NicolausUpgradeHold ➝ Buy$30.00 ➝ $38.00



#10 - Smith & Nephew (NYSE:SNN)

Consensus Rating
Hold
Rating Score
2.4
Ratings Breakdown
4 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
N/A

About Smith & Nephew

Smith & Nephew logoSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/8/2023UBS GroupUpgradeSell ➝ Neutral
4/27/2023HSBCDowngradeBuy ➝ Hold
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/29/2023BarclaysDowngradeOverweight ➝ Underweight
3/7/2023Sanford C. BernsteinInitiated CoverageOutperform
3/1/2023Liberum CapitalUpgradeHold ➝ Buy
2/22/2023UBS GroupBoost Price TargetGBX 970 ➝ GBX 1,000
2/22/2023BarclaysLower Price TargetGBX 1,500 ➝ GBX 1,480
2/16/2023Liberum CapitalInitiated CoverageHold
12/12/2022CitigroupInitiated CoverageBuy



#11 - Banco Bilbao Vizcaya Argentaria (NYSE:BBVA)

Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
2 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
N/A

About Banco Bilbao Vizcaya Argentaria

Banco Bilbao Vizcaya Argentaria logoBanco Bilbao Vizcaya Argentaria, SA, together with its subsidiaries, provides retail banking, wholesale banking, and asset management services. It offers current accounts; and demand, savings, overnight, time, term, and subordinated deposits. The company also provides loan products; deals in securities; leasing, factoring, brokerage, and asset management services; and manages pension and investment funds. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/5/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
5/26/2023BarclaysInitiated CoverageEqual Weight
4/28/2023HSBCUpgradeHold ➝ Buy
3/31/2023Keefe, Bruyette & WoodsUpgradeUnderperform ➝ Market Perform
1/24/2023Societe GeneraleDowngradeBuy ➝ Hold
12/8/2022AlphaValueUpgradeBuy
11/7/2022JPMorgan Chase & Co.Boost Price Target€6.70 ➝ €6.90
11/1/2022Berenberg BankBoost Price Target€5.30 ➝ €5.80
11/1/2022Deutsche Bank AktiengesellschaftBoost Price Target€6.70 ➝ €7.00
10/31/2022Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral€5.20 ➝ €5.50



#12 - Brookfield (NYSE:BN)

Consensus Rating
Moderate Buy
Rating Score
2.9
Ratings Breakdown
5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$47.60 (45.0% Upside)

About Brookfield

Brookfield logoBrookfield Corporation is an alternative asset manager and REIT/Real Estate Investment Manager firm focuses on real estate, renewable power, infrastructure and venture capital and private equity assets. It manages a range of public and private investment products and services for institutional and retail clients. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/14/2023Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$50.00 ➝ $48.00
8/31/2023CSFBLower Price TargetOutperform$42.00 ➝ $41.00
8/31/2023Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$42.00 ➝ $41.00
8/14/2023Royal Bank of CanadaLower Price TargetOutperform$52.00 ➝ $50.00
8/14/2023TD SecuritiesBoost Price TargetAction List Buy$60.00 ➝ $61.00
8/11/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold
8/8/2023TD SecuritiesLower Price TargetAction List Buy$61.00 ➝ $60.00
5/12/2023Keefe, Bruyette & WoodsDowngradeOutperform ➝ Market Perform
3/20/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform$41.00
2/10/2023TD SecuritiesLower Price TargetAction List Buy$63.00 ➝ $62.00



#13 - TKO Group (NYSE:TKO)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$127.00 (51.6% Upside)

About TKO Group

TKO Group logoTKO Group Holdings, Inc operates as a sports and entertainment company. The company produces live events, as well as broadcasts to TV households across approximately 170 countries. Its digital offerings include UFC FIGHT PASS, a streaming service for combat sports. The company is also involved in sports entertainment business, including entertainment on television programming, premium live events, digital media, and publishing platforms. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/21/2023GuggenheimLower Price TargetBuy ➝ Buy$130.00 ➝ $126.00
9/15/2023UBS GroupInitiated CoverageBuy$123.00
9/12/2023Seaport Res PtnUpgradeNeutral ➝ Buy
9/12/2023GuggenheimInitiated CoverageBuy$130.00
9/12/2023Roth MkmInitiated CoverageBuy$132.00



#14 - MSC Industrial Direct (NYSE:MSM)

Consensus Rating
Moderate Buy
Rating Score
2.5
Ratings Breakdown
3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$96.17 (1.1% Upside)

About MSC Industrial Direct

MSC Industrial Direct logoMSC Industrial Direct Co, Inc, together with its subsidiaries, distributes metalworking and maintenance, repair, and operations (MRO) products and services in the United States, Canada, Mexico, and the United Kingdom. Its MRO products include cutting tools, measuring instruments, tooling components, metalworking products, fasteners, flat stock products, raw materials, abrasives, machinery hand and power tools, safety and janitorial supplies, plumbing supplies, materials handling products, power transmission components, and electrical supplies. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/30/2023JPMorgan Chase & Co.Boost Price TargetNeutral$86.00 ➝ $89.00
6/30/2023Robert W. BairdBoost Price TargetOutperform$104.00 ➝ $110.00
4/21/2023KeyCorpBoost Price TargetOverweight$97.00 ➝ $105.00
4/5/2023KeyCorpBoost Price TargetOverweight$93.00 ➝ $97.00
4/5/2023JPMorgan Chase & Co.Boost Price TargetNeutral$80.00 ➝ $86.00
4/5/2023StephensReiterated RatingOverweight$100.00
4/5/2023Loop CapitalBoost Price TargetHold$82.00 ➝ $89.00
4/5/2023Robert W. BairdBoost Price TargetOutperform$95.00 ➝ $104.00
1/6/2023Robert W. BairdBoost Price Target$92.00 ➝ $95.00
10/17/2022Jefferies Financial GroupReiterated RatingHold$84.00



#15 - CEMEX (NYSE:CX)

Consensus Rating
Hold
Rating Score
2.4
Ratings Breakdown
2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$8.52 (27.5% Upside)

About CEMEX

CEMEX logoCEMEX, SAB. de C.V., together with its subsidiaries, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials worldwide. The company also offers asphalt, concrete blocks, concrete block paving, rail sleepers, and flooring systems; architectural concrete products; and box culverts, bridges, drainage basins, barriers, and parking curbs. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/28/2023Morgan StanleyBoost Price Target$9.00 ➝ $12.00
7/28/2023BarclaysBoost Price Target$8.00 ➝ $9.00
7/28/2023JPMorgan Chase & Co.Boost Price TargetOverweight$8.00 ➝ $9.00
7/17/2023BarclaysBoost Price Target$7.00 ➝ $8.00
5/15/2023Bank of AmericaDowngradeBuy ➝ Neutral$6.80 ➝ $7.20
5/5/2023CitigroupDowngradeBuy ➝ Neutral
5/3/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$5.90 ➝ $9.00
2/16/2023The Goldman Sachs GroupBoost Price TargetNeutral$5.20 ➝ $5.90
12/8/2022Redburn PartnersInitiated CoverageNeutral$4.90
9/20/2022BNP ParibasDowngradeOutperform ➝ Neutral$4.00



#16 - Science Applications International (NYSE:SAIC)

Consensus Rating
Hold
Rating Score
2.0
Ratings Breakdown
1 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$113.00 (7.2% Upside)

About Science Applications International

Science Applications International logoScience Applications International Corporation provides technical, engineering, and enterprise information technology (IT) services primarily in the United States. The company's offerings include engineering; technology integration; IT modernization; maintenance of ground and maritime systems; logistics; training and simulation; operation and program support services; and end-to-end services, such as design, development, integration, deployment, management and operations, sustainment, and security of its customers' IT infrastructure, as well as cloud migration, managed services, infrastructure modernization, and enterprise IT-as-a-service solutions; and data management platform solutions. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/8/2023Wells Fargo & CompanyBoost Price Target$114.00 ➝ $116.00
6/6/2023Truist FinancialLower Price Target$120.00 ➝ $115.00
4/11/2023Stifel NicolausBoost Price TargetHold$110.00 ➝ $112.00
4/5/2023The Goldman Sachs GroupBoost Price TargetSell$90.00 ➝ $97.00
4/4/2023Wells Fargo & CompanyLower Price TargetEqual Weight$121.00 ➝ $118.00
4/4/2023CitigroupLower Price TargetBuy$141.00 ➝ $127.00
1/3/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$108.00 ➝ $114.00
12/9/2022Morgan StanleyBoost Price Target$99.00 ➝ $108.00
12/8/2022CitigroupInitiated CoverageBuy$141.00
12/6/2022Truist FinancialBoost Price Target$105.00 ➝ $120.00



#17 - Kinross Gold (NYSE:KGC)

Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
5 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$6.24 (25.3% Upside)

About Kinross Gold

Kinross Gold logoKinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of gold properties principally in the United States, Brazil, Chile, Canada, and Mauritania. It is also involved in the extraction and processing of gold-containing ores; reclamation of gold mining properties; and production and sale of silver. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/11/2023DesjardinsInitiated CoverageBuy
8/17/2023CSFBBoost Price TargetNegative$5.25 ➝ $5.50
8/4/2023ScotiabankBoost Price TargetOutperform$6.25 ➝ $6.50
8/4/2023CIBCBoost Price TargetOutperform$6.60 ➝ $6.75
4/5/2023Bank of AmericaDowngradeBuy ➝ Underperform$4.70
2/17/2023TD SecuritiesLower Price TargetBuy$6.50 ➝ $6.00
1/31/2023Raymond JamesBoost Price TargetMarket Perform$4.50 ➝ $5.00
1/30/2023BarclaysDowngradeOverweight ➝ Equal Weight$5.00
1/13/2023National Bank FinancialBoost Price TargetC$8.25 ➝ C$8.50
12/6/2022Royal Bank of CanadaLower Price TargetSector Perform$6.00 ➝ $4.00



#18 - Dr. Reddy's Laboratories (NYSE:RDY)

Consensus Rating
Hold
Rating Score
2.0
Ratings Breakdown
2 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$70.00 (5.3% Upside)

About Dr. Reddy's Laboratories

Dr. ReddyDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/29/2023HSBCDowngradeBuy ➝ Hold
6/1/2023BarclaysBoost Price Target$67.00 ➝ $70.00
5/18/2023Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
3/17/2023Bank of AmericaUpgradeNeutral ➝ Buy
1/30/2023JPMorgan Chase & Co.Initiated CoverageUnderweight
11/14/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform
10/31/2022BarclaysBoost Price TargetOverweight$66.00 ➝ $67.00
10/25/2022BarclaysLower Price TargetOverweight$69.00 ➝ $66.00
9/12/2022BarclaysBoost Price TargetOverweight$68.00 ➝ $69.00
5/24/2022BarclaysBoost Price TargetOverweight$69.00 ➝ $70.00



#19 - Bio-Rad Laboratories (NYSE:BIO)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$533.00 (51.0% Upside)

About Bio-Rad Laboratories

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/7/2023Wells Fargo & CompanyLower Price TargetOverweight ➝ Overweight$550.00 ➝ $525.00
8/4/2023Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$522.00 ➝ $524.00
8/4/2023Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$580.00 ➝ $550.00
6/16/2023Wells Fargo & CompanyInitiated CoverageOverweight$550.00
2/17/2023Royal Bank of CanadaBoost Price TargetOutperform$571.00 ➝ $579.00
2/17/2023Credit Suisse GroupBoost Price TargetOutperform$640.00 ➝ $680.00
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$565.00
10/28/2022Credit Suisse GroupLower Price TargetOutperform$715.00 ➝ $640.00
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$715.00
7/8/2022CitigroupLower Price TargetBuy$750.00 ➝ $700.00



#20 - Jazz Pharmaceuticals (NASDAQ:JAZZ)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$206.67 (56.9% Upside)

About Jazz Pharmaceuticals

Jazz Pharmaceuticals logoJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
8/14/2023Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$210.00 ➝ $180.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$204.00
8/10/2023Bank of AmericaBoost Price TargetBuy ➝ Buy$204.00 ➝ $217.00
8/10/2023Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$203.00 ➝ $201.00
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$226.00
7/10/2023Cantor FitzgeraldReiterated RatingOverweight
5/11/2023Royal Bank of CanadaLower Price Target$207.00 ➝ $202.00
5/11/2023Needham & Company LLCBoost Price Target$205.00 ➝ $212.00
3/6/2023HC WainwrightReiterated RatingBuy$204.00


More Investing Slideshows:




My Account -